InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) announced the filing of a patent for synthetic cannabinoids on Sept 12, 2017, which the company claims are “are identical to those found in nature”.
Once in place, the patent will provide protection to (CSE: IN) (OTCQB: IMLFF) for InMed’s E. coli-based expression system to manufacture any of the 90+ cannabinoid compounds that may have a medical impact on important human diseases.
This is BIG NEWS to the scientific community which has wrestled with the inconsistency of cannabinoids from natural marijuana growers and the regime of other naturally occurring biopharma components within the Weed itself, or in simple terms contaminants. The purer the Cannabinoids the better the lab results.
This places (CSE: IN) (OTCQB: IMLFF) in a KING MAKER status amongst medical marijuana companies worldwide. Why? Because they’ll own the toll road through their patents. Its akin to Google’s search engine, whose own patents held Yahoo (NASDAQ: YHOO) and MicroSoft (NASDAQ: MSFT) at bay with their own search engines.
InMed’s shares (OTC) where trading at just over $0.21 before the news was released. Since then, (CSE: IN; OTCQB: IMLFF) shares rose to a high of $0.36 shares, settling back to trade at $0.33 on Sept 19, 2017, according to MarketWatch.
Dr. Vikramaditya Yadav, Assistant Professor of Chemical and Biological Engineering at University of British Columbia, a co-inventor of the biosynthesis technology, agreed with Financials Trend, calling the biosynthesis a “game changer.”
“In our extensive experimentation, the E. coli system is more robust and more efficient for the manufacturing of cannabinoids as compared to other microbial platforms,” Dr Yadav noted.
As biopharma stocks go, we see (CSE: IN; OTCQB: IMLFF) as becoming a FIVE BAGGER, given time for InMed Pharmaceuticals to complete its patent protection. The keywords here are accumulation and patience.
We do not see InMed skyrocketing to fame and fortune overnight. But at these trading prices it’s a bargain bin buy for shoppers!
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of financialstrend.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.financialstrend.com/disclaimer